TherapeuticsMD (TXMD) Common Equity (2010 - 2026)
TherapeuticsMD's (TXMD) quarterly Common Equity came in at $27.0 million in Q1 2026, up 0.87% YoY from $26.7 million in Q1 2025, and little changed on a QoQ basis from $26.9 million in Q4 2025.
TherapeuticsMD (TXMD) Common Equity (2010 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has 17 years of Common Equity data on file, last reported at $27.0 million in Q1 2026.
- Quarterly Common Equity rose 0.87% year-over-year to $27.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.0 million (up 0.87% YoY) and the FY2025 annual result came in at $26.9 million, down 1.8% from the prior year.
- Common Equity steadied at $27.0 million in Q1 2026, from $26.9 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $35.1 million in Q4 2022 to a low of -$140.6 million in Q1 2022.
- A 5-year average of $11.0 million and a median of $27.4 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 1383.22% — and 2023, when it soared 219.68%.
- Tracing TXMD's Common Equity over 5 years: stood at $35.1 million in 2022, then retreated by 16.66% to $29.3 million in 2023, then retreated by 6.55% to $27.4 million in 2024, then decreased by 1.8% to $26.9 million in 2025, then gained by 0.36% to $27.0 million in 2026.
- The last three Common Equity figures came in at $27.0 million (Q1 2026), $26.9 million (Q4 2025), and $27.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.23 Bn | 43.26 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.87 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 32.51 Bn | 30.84 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.66 Bn | 22.86 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.83 Bn | 17.94 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.49 Bn | 15.10 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | TherapeuticsMD | 23.84 Mn | 14.65 Mn | - | 27.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.13 Mn |
| Mar 31, 2026 | 26.97 Mn |
| Dec 31, 2025 | 26.88 Mn |
| Sep 30, 2025 | 27.44 Mn |
| Jun 30, 2025 | 27.29 Mn |
| Mar 31, 2025 | 26.74 Mn |
| Dec 31, 2024 | 27.37 Mn |
| Sep 30, 2024 | 27.09 Mn |
| Jun 30, 2024 | 27.67 Mn |
| Mar 31, 2024 | 28.66 Mn |
| Dec 31, 2023 | 29.29 Mn |
| Sep 30, 2023 | 28.05 Mn |
| Jun 30, 2023 | 31.20 Mn |
| Mar 31, 2023 | 32.02 Mn |
| Dec 31, 2022 | 35.14 Mn |
| Sep 30, 2022 | -48.27 Mn |
| Jun 30, 2022 | -26.07 Mn |
| Mar 31, 2022 | -140.58 Mn |
| Dec 31, 2021 | -93.62 Mn |
| Sep 30, 2021 | -57.36 Mn |